Literature DB >> 18417668

Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.

Kristian S Omland1, April Brys, David Lansky, Kristin Clement, Freyja Lynn.   

Abstract

The anthrax lethal toxin neutralization assay (TNA) will likely be used to correlate the protection offered by new anthrax vaccines in animal models to the immunogenicity that will be provided in humans. TNA data are being generated in several different laboratories to measure the immune responses in rabbits, nonhuman primates, and humans. In order to compare data among species and laboratories, a collaborative study was conducted in which 108 samples from the three species were analyzed in seven independent laboratories. Six of the seven laboratories had participated in an interlaboratory technology transfer of the TNA. Analysis of the titration curves generated by samples from each species indicated that the behaviors of the samples from all species were similar; the upper and lower asymptotes and the slopes of the curves were less than 30% divergent from those for human reference material. Dilutional linearity was consistent among samples from each species, with spike to effective dilution at 50% inhibition (ED(50)) slopes of less than 1.2 for all species. Agreement among the laboratories with consensus values was within 10% of the ED(50)s for all samples and within 7.5% of the quotients of the test sample ED(50) and the reference standard ED(50) (NF(50)s) for all samples. The relative standard deviations obtained when data from all laboratories and for all species were combined were 45% for the ED(50)s and 35% for the NF(50)s. These precision data suggest that the NF(50) readout may normalize the values generated by different laboratories. This study demonstrates that the TNA is a panspecies assay that can be performed in several different laboratories with a high degree of quantitative agreement and precision.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417668      PMCID: PMC2446612          DOI: 10.1128/CVI.00003-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  22 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Authors:  Phillip R Pittman; Gina Kim-Ahn; Dominique Y Pifat; Kevin Coonan; Paul Gibbs; Steve Little; Judith G Pace-Templeton; Robert Myers; Gerald W Parker; Arthur M Friedlander
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

Review 4.  Structure and function of anthrax toxin.

Authors:  D B Lacy; R J Collier
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

5.  Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.

Authors:  V A Semenova; E Steward-Clark; K L Stamey; T H Taylor; D S Schmidt; S K Martin; N Marano; C P Quinn
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

6.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

7.  Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Authors:  Conrad P Quinn; Peter M Dull; Vera Semenova; Han Li; Shane Crotty; Thomas H Taylor; Evelene Steward-Clark; Karen L Stamey; Daniel S Schmidt; Kelly Wallace Stinson; Alison E Freeman; Cheryl M Elie; Sandra K Martin; Carolyn Greene; Rachael D Aubert; John Glidewell; Bradley A Perkins; Rafi Ahmed; David S Stephens
Journal:  J Infect Dis       Date:  2004-08-30       Impact factor: 5.226

8.  Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.

Authors:  Han Li; Stephen D Soroka; Thomas H Taylor; Karen L Stamey; Kelly Wallace Stinson; Alison E Freeman; Darbi R Abramson; Rita Desai; Li X Cronin; J Wade Oxford; Joseph Caba; Cynthia Pleatman; Sonal Pathak; Daniel S Schmidt; Vera A Semenova; Sandra K Martin; Patricia P Wilkins; Conrad P Quinn
Journal:  J Immunol Methods       Date:  2008-02-08       Impact factor: 2.303

9.  Validation of the anthrax lethal toxin neutralization assay.

Authors:  Donna Hering; William Thompson; John Hewetson; Stephen Little; Sarah Norris; Judith Pace-Templeton
Journal:  Biologicals       Date:  2004-03       Impact factor: 1.856

10.  Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Authors:  Conrad P Quinn; Vera A Semenova; Cheryl M Elie; Sandra Romero-Steiner; Carolyn Greene; Han Li; Karen Stamey; Evelene Steward-Clark; Daniel S Schmidt; Elizabeth Mothershed; Janet Pruckler; Stephanie Schwartz; Robert F Benson; Leta O Helsel; Patricia F Holder; Scott E Johnson; Molly Kellum; Trudy Messmer; W Lanier Thacker; Lilah Besser; Brian D Plikaytis; Thomas H Taylor; Alison E Freeman; Kelly J Wallace; Peter Dull; Jim Sejvar; Erica Bruce; Rosa Moreno; Anne Schuchat; Jairam R Lingappa; Sandra K Martin; John Walls; Melinda Bronsdon; George M Carlone; Mary Bajani-Ari; David A Ashford; David S Stephens; Bradley A Perkins
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more
  20 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

3.  Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.

Authors:  Anita Verma; Miriam M Ngundi; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

4.  The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example.

Authors:  Molly A Hughes; Drusilla L Burns; Stephen J Juris; Wei-Jen Tang; Kristin H Clement; Linda J Eaton; Cassandra D Kelly-Cirino; Marian L McKee; Bradford S Powell; Brian L Bishop; Thomas L Rudge; Nancy Shine; Anita Verma; Melissa Swope Willis; Stephen A Morse
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

5.  Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Authors:  Boris Ionin; Robert J Hopkins; Brett Pleune; Gloria S Sivko; Frances M Reid; Kristin H Clement; Thomas L Rudge; Gregory V Stark; Alison Innes; Suha Sari; Tina Guina; Cris Howard; Jeffrey Smith; M Lisa Swoboda; Ekaterina Vert-Wong; Virginia Johnson; Gary S Nabors; Mario H Skiadopoulos
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

6.  Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.

Authors:  Kristin H Clement; Thomas L Rudge; Heather J Mayfield; Lena A Carlton; Arelis Hester; Nancy A Niemuth; Carol L Sabourin; April M Brys; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

7.  Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.

Authors:  G S Sivko; G V Stark; K P Tordoff; K L Taylor; E Glaze; M VanRaden; J M Schiffer; J A Hewitt; C P Quinn; E O Nuzum
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

8.  Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Authors:  Michael P Fay; Dean A Follmann; Freyja Lynn; Jarad M Schiffer; Gregory V Stark; Robert Kohberger; Conrad P Quinn; Edwin O Nuzum
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

9.  Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.

Authors:  David I Bernstein; Lisa Jackson; Shital M Patel; Hana M El Sahly; Paul Spearman; Nadine Rouphael; Thomas L Rudge; Heather Hill; Johannes B Goll
Journal:  Vaccine       Date:  2014-09-17       Impact factor: 3.641

10.  Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

Authors:  Robert J Hopkins; Nancy F Daczkowski; Paulina E Kaptur; Derek Muse; Eric Sheldon; Craig LaForce; Suha Sari; Thomas L Rudge; Edward Bernton
Journal:  Vaccine       Date:  2013-05-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.